Indian Pharma Sector Forecast 2022-2026: Rise in Continuous Investments by Multinational Companies and Exports to Drive Market – ResearchAndMarkets.com

Indian Pharma Sector Forecast 2022-2026: Rise in Continuous Investments by Multinational Companies and Exports to Drive Market – ResearchAndMarkets.com




Indian Pharma Sector Forecast 2022-2026: Rise in Continuous Investments by Multinational Companies and Exports to Drive Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Indian Pharma Sector Forecast 2026” report has been added to ResearchAndMarkets.com’s offering.

The Indian pharma industry has always been a leading industrial sector in the country, with a paralleled dominance of both domestic and foreign pharma companies. As a result of the vast potential held by the industry, it was estimated to have generated revenue worth US$ 49 Billion in FY 2021. Growing population of middle-class, rapid shift towards urbanization, enhanced medical infrastructure, increase in health insurance and lifestyle-related disease are some of the major factors for the growth of the industry.

According to this new research report, the rise in continuous investments by multinational companies and exports project a double-digit growth in near future. A large percentage of pharma products produced in India are exported, which has led the leading players to expand their reach into the Western nations. Due to the investments in R&D and the quest for more and more ANDA filings, the clinical trials market is growing at blistering pace. For comprehensive outlook of the industry, our in-depth and extensive research covers various segment ranging from the export and domestic market, bulk drugs & formulations to branded & generic drugs, etc.

The progress in the reach to medicines among Indians sets the baseline for the optimistic future outlook of the pharmaceutical market. The focus of the industry will shift towards capitalizing the potential of Tier-III and rural areas. Sectors such as biosimilars and CRAMS will continue pave way for the pharmaceutical market during the forecast period (FY 2022-2026).

The report offers a comprehensive statistical and analytical overview of the Indian pharmaceutical industry. It offers data on past, present, and future trends, with a focus on the pharmaceutical market’s overall structure, makeup, and operation. The research goes into great detail about the opportunities and challenges that are predicted to occur both within and outside the pharmaceutical industry.

The research also looks at the pharmaceutical industry’s regulatory framework and distribution structure. It has thoroughly investigated current market trends, developments, and competitive landscapes in order to help clients comprehend the market structure and its trajectory in the coming years. It also gives a quick rundown of the demographics and healthcare profile in order to assess the pharmaceutical market in terms of demand, spending, and potential future direction.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Market Drivers

4. Indian Pharmaceutical Industry

5. Market Segmentation

6. Distribution Channel Analysis

7. Regulatory Overview

8. Growth Accelerators

9. Competitive Landscape

Companies Mentioned

  • Aurobindo Pharma
  • Cipla Limited
  • Dr. Reddys Labs
  • Sun Pharma
  • Lupin Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/4d6urs

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900